Effects of Pulmonary Rehabilitation on Skeletal Muscle in COPD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-02

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a former study, the investigator observed significant differences in the response to pulmonary rehabilitation between COPD patients with the "normal" genetic variant of alpha-1 antitrypsin (PiMM) and those with a homozygous deficient variant (PiZZ) (Jarosch et al., 2016, DOI: 10.1159/000449509). PiZZ COPD patients showed less improvement in exercise capacity compared to PiMM patients. This latter finding was mirrored by an increase of oxidative myofiber type I proportion - that is important for aerobic exercises in daily life - in PiMM but not PiZZ patients.

Based on this finding of impaired skeletal muscle adaptation, the aim of this study is to compare the effects of pulmonary rehabilitation including exercise training on a) specific enzymes of energy metabolism reflecting the oxidative capacity of the skeletal muscle and b) the analogue gene expression of these oxidative enzymes in a cohort of PiMM and PiZZ COPD patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients

NCT03802357

Chronic Obstructive Pulmonary Disease Alpha 1-Antitrypsin Deficiency

UNKNOWN NA

Effects of Rehabilitation on Muscle Fibre Composition and Capillaries in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01715337

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis

NCT01772667

Idiopathic Pulmonary Fibrosis

COMPLETED NA

Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients

NCT01380626

Chronic Obstructive Pulmonary Disease Alpha-1-antitrypsin-deficiency

COMPLETED NA

Pulmonary Rehabilitation in End-Stage Liver Disease

NCT03266575

End Stage Liver Disease

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PiMM patients

COPD patients with the Alpha-1 antitrypsin genetic variant "PiMM" (Smoking-related COPD)

Group Type ACTIVE_COMPARATOR

Pulmonary rehabilitation

Intervention Type PROCEDURE

3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)

PiZZ patients

COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)

Group Type EXPERIMENTAL

Pulmonary rehabilitation

Intervention Type PROCEDURE

3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulmonary rehabilitation

3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic obstructive pulmonary disease
* phenotype PiMM or PiZZ
* written informed consent

Exclusion Criteria

* any comorbidities that prevent patients from participating in an exercise Training program
* necessity of anticoagulant therapy
* other genetic variants of alpha-1 antitrypsin than PiMM or PiZZ

Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No